Related Experiment Videos
[Effects of TCGF (T-cell growth factor) on experimental malignant glioma-specific killer T-cell]
Abstract:
The immunoregulatory effects of TCGF (T-cell growth factor) on the generation and growth of syngeneic murine malignant glioma (20-methylcholanthrene-induced 203-glioma)-specific killer T-cell were investigated in C57BL/6 adult mice in order to clarify the immunopotential usefulness for anti-tumor local adoptive immunotherapy against malignant brain tumor. TCGF was prepared and assayed. Briefly, 5 x 10(6) ml mouse spleen cells were cultured with 2 microgram/ml concanavalin A in RPMI-1640 medium supplemented with 2% fetal calf serum for 24 hours. Culture supernatants were concentrated by ammonium sulphate precipitation (55 to 80% saturation) and purified by gel filtration (Sephadex G-100, a molecular weight from 30 to 36,000 daltons) and ion exchange chromatography (DEAE-cellulose, elution with 0.15 M in NaCl at ph 7.4). The purified TCGF had no IFN activity. Assays for TCGF was performed for quantitative analysis using 203-glioma-specific killer T cell clone (G-CTLL), which was obtained by limiting dilution method (0.3 cells/well in 96 well microtiter plate) and maintained for over 6 months in the presence of TCGF. Titer (U/ml) of TCGF was defined as the quantity of TCGF required to obtain one-half of the maximal stimulation of G-CTLL proliferation assay. It was confirmed that the specific killer T-cell against 203-glioma was generated in mice after intracranial as well as subcutaneous inoculation of the tumor cells. The killer T-cell activity of spleen cells, however, began to be severely impaired 2 weeks after intracranial inoculation concurrently with the increased intracranial pressure due to developing the tumor growth. Sensitized lymphocytes obtained from intracranial and subcutaneous tumor-bearing mice were assessed for CTL (cytotoxic T-lymphocyte) activity in MLTC (mixed lymphocyte-tumor cell culture) for 18 hours by microcytotoxicity assay. The specific cytotoxicity against 203-glioma cells was enhanced when sensitized lymphocytes from intracranial and subcutaneous tumor-bearing mice were pre-cultured with optimal TCGF (20 U/ml) for over 5 days. After the treatment of sensitized lymphocytes with anti-Thy-1 monoclonal antibody and complement, however, the specific cytotoxicity of sensitized lymphocytes was eliminated almost completely. Therefore, it was thought that TCGF possesses immunoregulatory effects of enhancement of killer T-cell activity. On the contrary, TCGF had no influence on normal T lymphocytes and the growth of 203-glioma cells in vitro.(ABSTRACT TRUNCATED AT 400 WORDS)
Insights
T-cell growth factor (TCGF) enhances the activity of killer T-cells specific for malignant glioma. This finding suggests TCGF
Area of Science:
- Immunology
- Oncology
- Neuroscience
Context:
- Malignant brain tumors, specifically gliomas, pose significant therapeutic challenges.
- Adoptive immunotherapy strategies are being explored to combat these tumors.
- The role of T-cell mediated immunity in brain tumor rejection is critical.
Purpose:
- To investigate the immunoregulatory effects of T-cell growth factor (TCGF) on the generation and activity of malignant glioma-specific killer T-cells.
- To evaluate the potential of TCGF in enhancing anti-tumor adoptive immunotherapy for malignant brain tumors.
- To characterize the specific mechanisms by which TCGF influences cytotoxic T-lymphocyte (CTL) responses against 203-glioma.
Summary:
- TCGF was purified and characterized, showing no interferon activity.
- Malignant glioma-specific killer T-cells (G-CTLL) were generated and maintained using TCGF.
- Pre-culturing sensitized lymphocytes with TCGF significantly enhanced their specific cytotoxicity against 203-glioma cells.
- The enhanced cytotoxicity was confirmed to be T-cell dependent, as it was eliminated by anti-Thy-1 antibody treatment.
- TCGF demonstrated immunoregulatory effects by enhancing killer T-cell activity without affecting normal T-lymphocytes or glioma cell growth in vitro.
Impact:
- TCGF shows promise as an immunomodulatory agent for enhancing T-cell based anti-cancer therapies.
- This research provides a foundation for developing novel immunotherapies targeting malignant brain tumors.
- Understanding TCGF's role could lead to improved treatment strategies for patients with gliomas.